Notice of Results

Stem Cell Sciences plc
01 March 2006


For Immediate Release                                               1 March 2006

                             Stem Cell Sciences plc

                         Notice of Preliminary Results


Stem Cell Sciences plc, the global stem cell company focused on the application 
of stem cell technologies to cell culture media, cell based drug screens and 
novel cell therapies, will be announcing its preliminary results for the year 
ended 31 December 2005 on Thursday 30 March 2006.

                                    - Ends -

For further information please contact:

Weber Shandwick Square Mile                                        020 7067 0725
Yvonne Alexander


Notes to Editor

Stem Cell Sciences plc (SCS) is a global biotechnology company focused on the
development of stem cell technologies. The Company has established a leading
intellectual property (IP) and technology portfolio that enables the commercial
application of stem cells in pharmaceutical and biotechnology drug discovery,
providing the Company with an early-stage revenue stream. In the longer term,
the Company is developing regenerative, cell-based therapies.

Stem Cell Sciences has four business units focused on key sustainable business
strategies. SC Proven provides serum free, cell culture media and reagents that
enable the growth of stem cells. The first commercially available product, a
mouse embryonic stem cell growth medium, has been exclusively licensed for
manufacture and marketing to Chemicon, a division of Serologicals Inc. SC
Licensing licenses its proprietary technologies such as Internal Ribosome Entry
Site (IRES) and Stem Cell Selection for application in laboratory-based research
and discovery. SC Services will provide cell production for research and
high-throughput drug screening. SC Therapies first program is being undertaken
by SCS's Japanese affiliate, which recently announced the exclusive licensing of
human multipotent adipocyte-derived (hMADS) for use in an experimental cell
based therapy programme against Duchene's Muscular Dystrophy form the basis for
a degenerative diseases focused pre-clinical programme.

SCS plc is a global Group with operations in the UK, Australia and Japan. Each
company is affiliated with academic stem cell centres of excellence in order to
access and commercialize new IP developing in the field. These include the
Institute of Stem Cell Research, Edinburgh, UK; RIKEN Centre for Development
Biology, Japan and the Australian Stem Cell Centre, Melbourne, Australia.

SCS, which listed on the London Alternative Investment Market in July 2005, was
founded in 1994 to commercialize findings from the Institute of Stem Cell
Research at the University of Edinburgh, UK, and Monash University, Melbourne,
Australia. The Company is a participant in two research projects under the
European Union's Framework Six Programme for Research and Technology Development
and is a contributor to the UK Stem Cells Initiative.





                      This information is provided by RNS
            The company news service from the London Stock Exchange